Table 4.
Subgroup analysis of complete response (CR) in overall phase (OP)
| Subgroup | Fosaprepitant group | Aprepitant group | p value | ||
|---|---|---|---|---|---|
| Response (n) | CR (%) | Response (n) | CR (%) | ||
| Prior chemotherapy | |||||
| No | 102 | 84.30 | 112 | 91.06 | .1217 |
| Yes | 191 | 92.27 | 182 | 93.81 | .5636 |
| Sex | |||||
| Male | 150 | 92.02 | 154 | 94.48 | .5086 |
| Female | 143 | 86.67 | 140 | 90.91 | .2885 |
| Age | |||||
| <65 | 246 | 90.11 | 246 | 92.48 | .3619 |
| ≥65 | 47 | 85.45 | 48 | 94.12 | .2052 |
| ECOG | |||||
| 0 | 53 | 82.81 | 59 | 92.19 | .1802 |
| 1, 2 | 239 | 90.87 | 235 | 92.89 | .4251 |
| Cisplatin‐contained | |||||
| No | 57 | 87.69 | 78 | 93.98 | .2437 |
| Yes | 236 | 89.73 | 216 | 92.31 | .3501 |